Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Wearable Diagnostic for Detection of COVID-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04742569
Recruitment Status : Recruiting
First Posted : February 8, 2021
Last Update Posted : August 16, 2021
Sponsor:
Collaborators:
BioIntelliSense, Inc
Phillips North America, LLC
University of Colorado, Denver
United States Department of Defense
Information provided by (Responsible Party):
ClinOne, Inc.

Tracking Information
First Submitted Date January 14, 2021
First Posted Date February 8, 2021
Last Update Posted Date August 16, 2021
Actual Study Start Date December 21, 2020
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: February 5, 2021)
  • The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor. [ Time Frame: 14 days ]
    Biometric data will be measured for 14 days using the application of the BioSticker on the upper left side of the chest.
  • The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor. [ Time Frame: 14 days ]
    Vital Signs measurements will be collected for 14 days using the application of the BioSticker on the upper left side of the chest.
  • The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms. [ Time Frame: 14 days ]
    Symptom tracking data will be collected through daily questionnaires for 14 consecutive days, administered through ClinOne. Health data known to be associated with COVID-19 risk and severity, including comorbid conditions, risk factors, and demographic data will be collected from subjects during screening and enrollment via the ClinOne study website.
  • The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19. [ Time Frame: 14 days ]
    BioSticker sensor data will be time-stamped and annotated against clinical events (e.g., fever, cough), symptom progression data, and other indicators of infection as they are identified. Weighting coefficients for predictive algorithms will be tuned and algorithms will be iteratively refined using machine learning methods and small batches of data anticipated to include between 20 and 50 positive cases per set, and validated against sensor data obtained from COVID-19-negative subjects.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: February 5, 2021)
The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms. [ Time Frame: 14 days ]
Individual-level experiential feedback will be reported through participant symptom- tracking and diagnostic questionnaires for 14 consecutive days.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Wearable Diagnostic for Detection of COVID-19 Infection
Official Title Wearable Diagnostic for Detection of COVID-19 Infection
Brief Summary The goals of this study are 1) to validate the use of a wearable diagnostic capability and software as a medical device (SaMD) algorithm for the pre or early-symptomatic detection of COVID-19 infection, 2) assess the wearable device on the subjects, and 3) ensure data are collected, securely stored, and easily read and interpreted by non-laboratory personnel.
Detailed Description

This is an open label iterative study designed to calibrate the algorithm to maximize its test characteristics. The sample size is derived from the minimum number of COVID-19 subjects required to evaluate algorithm sensitivity and specificity. A sample size of 200 true positive COVID-19 infections is anticipated to assess device predictive analytics. Assuming a six-month enrollment period, a 15 percent patient lost to follow-up rate, and a positive COVID-19 infection rate of 10 percent within the study population, a sample size of 2,352 subjects will be enrolled in this prospective study.

Primary Outcomes: The primary outcomes of interest are performance of the BioSticker multiparameter vital signs wearable and the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19 related signs and symptom in subjects prior to or coincident with a positive COVID-19 diagnostic test and the specificity of the BioSticker algorithms in distinguishing positive diagnosis of infection from negative diagnosis of infection among subjects. COVID-19 infection will be confirmed by both participant affirmation and diagnostic laboratory testing. Additional primary outcome is the intuitive presentation of affirmative diagnostic results from the BioSticker early detection algorithm(s).

Secondary Outcomes: The secondary outcomes of interest include correlation of biometric data indicators to individual-level experiential feedback reported through participant symptom-tracking and diagnostic questionnaires.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population

Cohort 1- Exposed/Early Symptomatic Group All adult subjects seeking a COVID-19 test and meeting enrollment criteria will be offered enrollment into this study.

The Inclusion Criteria are:

  1. Adults - 18 years of age and older
  2. Both genders, all races and ethnic groups
  3. English speaking adult subjects only

Cohort 2- Vaccine Group:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine

  1. Subjects who are scheduled to receive the COVID vaccination series through local and national clinics, health systems and pharmacies.
  2. Subjects who become aware of the study through public notices, postings, and advertisements, and other marketing efforts.
Condition COVID-19
Intervention Not Provided
Study Groups/Cohorts
  • Cohort 1- Exposed/Early Symptomatic

    The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.

    For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day.

  • CoHort 2- Pfizer or Moderna Vaccine
    Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: February 5, 2021)
2352
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 31, 2021
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Cohort 1- Exposed/ Early Symptomatic Group

Inclusion Criteria:

  1. age 18 or older;
  2. able to follow the study device wear instructions per the Instructions for Use;
  3. no positive viral test within 60 days prior to enrollment; and
  4. willing and able to provide written, informed consent.

Exclusion Criteria:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.

Cohort 1- Vaccine Group

Inclusion Criteria:

Subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series are eligible for the study if they are:

  1. Age 18 or older; 12 years of age -17 years of age are approved to participate in the vaccine Cohort portion of the study.
  2. scheduled to receive their first and second dose of the Pfizer/BioNTech or Moderna COVID-19 vaccine
  3. able to follow the study device wear instructions per the Instructions for Use;
  4. no positive viral test within 60 days prior to enrollment; and
  5. willing and able to provide written, informed consent.
  6. Willing and able to take an oral temperature

Exclusion Criteria:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series will be excluded from the study if they are or have any of the following:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.
  8. previously fully vaccinated subjects
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: ELIZABETH ESTERL, DNP, MS, RN 7207326231 eesterl@clinone.com
Contact: Joseph Ruybal, MS 7209847833 jruybal@clinone.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04742569
Other Study ID Numbers 1294415
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party ClinOne, Inc.
Study Sponsor ClinOne, Inc.
Collaborators
  • BioIntelliSense, Inc
  • Phillips North America, LLC
  • University of Colorado, Denver
  • United States Department of Defense
Investigators
Principal Investigator: James Mault, MD BioIntelliSense, Inc
PRS Account ClinOne, Inc.
Verification Date February 2021